Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00718419 · OUTCOME

Number of Participants Who Died Due to Progressive Disease During the 30 Days Following Discontinuation From Study Treatment

A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma · Source last updated 2020-09-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Study treatment discontinuation up to 30 days post study treatment discontinuation

Analysis population: All participants who received at least one dose of the study drug.

Groups in this outcome

Multiple Myeloma (MM)

Participants diagnosed with MM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days.

Waldenstrom's Macroglobulinemia (WM)

Participants diagnosed with WM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Multiple Myeloma (MM)14
Waldenstrom's Macroglobulinemia (WM)42

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma (MM)0Not reportedNot reportedNot reportedNot reported
Waldenstrom's Macroglobulinemia (WM)1Not reportedNot reportedNot reportedNot reported
Complete source fields
calculate Pct
false
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      14
    2. group Id
      OG001
      value
      42
    units
    Participants
groups
  1. description
    Participants diagnosed with MM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days.
    id
    OG000
    title
    Multiple Myeloma (MM)
  2. description
    Participants diagnosed with WM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days.
    id
    OG001
    title
    Waldenstrom's Macroglobulinemia (WM)
param Type
COUNT_OF_PARTICIPANTS
population Description
All participants who received at least one dose of the study drug.
reporting Status
POSTED
time Frame
Study treatment discontinuation up to 30 days post study treatment discontinuation
title
Number of Participants Who Died Due to Progressive Disease During the 30 Days Following Discontinuation From Study Treatment
type
OTHER_PRE_SPECIFIED
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice